Disease response and patient-reported outcomes among initiators of ixekizumab.
Shahriari M, Harrison RW, Burge R, Lin CY, Malatestinic WN, Goldblum OM, McLean RR, Crabtree MM, O'Brien J, Grace EL, Murage MJ.
Shahriari M, et al. Among authors: mclean rr.
J Dermatolog Treat. 2022 May;33(3):1538-1546. doi: 10.1080/09546634.2020.1853023. Epub 2020 Dec 2.
J Dermatolog Treat. 2022.
PMID: 33267635
Free article.